Detection of Drug-Resistant Tuberculosis by Xpert MTB/RIF in Swaziland
To the Editor: Tuberculosis is a major global health problem that has worsened with the increasing emergence of Mycobacterium tuberculosis (MTB) complex strains that are resistant to rifampin (RIF) and isoniazid. As recommended by the World Health Organization (WHO), the timely detection of drug resistance with the use of rapid molecular diagnostic tests, such as the Xpert MTB/RIF assay (Cepheid), is essential for appropriate treatment of patients with tuberculosis and for limiting the further spread of multidrug-resistant disease. 1,2
We used 24-loci mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) analysis and spoligotyping to perform classic genotypic analysis of MTB complex strains from the most recent (2009) national survey of tuberculosis-drug resistance in Swaziland, a country with a high prevalence of tuberculosis (945 cases per 100,000 persons, or approximately 1%). 3 We found that 38 of 125 multidrug-resistant strains (30%) that were isolated during the survey carried the rpoB I491F mutation, which confers resistance to rifampin (Table 1 ; and the Supplementary Appendix, available with the full text of this letter at NEJM .org). This mutation, which was previously reported with low frequency in clinical isolates from Hong Kong and Australia, 4 is not detected by the Xpert MTB/RIF assay.
Xpert MTB/RIF, a cartridge-based point-ofcare assay, is designed to identify rifampin resistance mutations in an 81-bp region of rpoB (codons 426 to 452). Its inability to detect the rpoB I491F outbreak strain raises new challenges, since Xpert MTB/RIF is used throughout most of Swaziland as the first-line diagnostic test for tuberculosis and for multidrug-resistant tuberculosis, as recommended by the WHO. 5 Thus, the circulation of strains with the rpoB I491F mutation substantially reduces the sensitivity of Xpert MTB/RIF-based diagnosis in Swaziland and presumably results in underdiagnosis and potentially inadequate treatment. This is problematic in a country where an estimated 26% of adults are infected with the human immunodeficiency virus (HIV) and 80% of patients with tuberculosis are coinfected with HIV. In addition, coinfected patients are more likely than 
